BR112016017317A8 - composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 - Google Patents
composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 Download PDFInfo
- Publication number
- BR112016017317A8 BR112016017317A8 BR112016017317A BR112016017317A BR112016017317A8 BR 112016017317 A8 BR112016017317 A8 BR 112016017317A8 BR 112016017317 A BR112016017317 A BR 112016017317A BR 112016017317 A BR112016017317 A BR 112016017317A BR 112016017317 A8 BR112016017317 A8 BR 112016017317A8
- Authority
- BR
- Brazil
- Prior art keywords
- trpa1
- compound
- prophylaxis
- drug
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
é provido um composto representado pela fórmula (i) [em que cada símbolo é como definido na descrição] ou um sal farmaceuticamente aceitável do mesmo. esse composto tem uma atividade antagonística de trpa1 excelente, que torna possível prover um antagonista de trpa1 e um medicamento que é útil para prevenir ou tratar doenças associadas à trpa1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-013729 | 2014-01-28 | ||
JP2014013729 | 2014-01-28 | ||
JP2014-160250 | 2014-08-06 | ||
JP2014160250 | 2014-08-06 | ||
PCT/JP2015/052415 WO2015115507A1 (ja) | 2014-01-28 | 2015-01-28 | 複素環スルホンアミド誘導体及びそれを含有する医薬 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112016017317A2 BR112016017317A2 (pt) | 2017-10-17 |
BR112016017317A8 true BR112016017317A8 (pt) | 2018-04-17 |
BR112016017317B1 BR112016017317B1 (pt) | 2023-04-11 |
Family
ID=53757079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016017317-1A BR112016017317B1 (pt) | 2014-01-28 | 2015-01-28 | Composto, e, uso de um composto |
Country Status (12)
Country | Link |
---|---|
US (1) | US10626112B2 (pt) |
EP (1) | EP3101015B1 (pt) |
JP (1) | JP6473420B2 (pt) |
KR (1) | KR20160135183A (pt) |
CN (1) | CN106458952B (pt) |
AU (1) | AU2015211852A1 (pt) |
BR (1) | BR112016017317B1 (pt) |
CA (1) | CA2938198A1 (pt) |
ES (1) | ES2759310T3 (pt) |
MX (1) | MX2016009794A (pt) |
RU (1) | RU2016134749A (pt) |
WO (1) | WO2015115507A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6700291B2 (ja) * | 2015-02-15 | 2020-05-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 1−(het)アリールスルホニル−(ピロリジン又はピペリジン)−2−カルボキサミド誘導体、及びtrpa1拮抗薬としてのそれらの使用 |
WO2017018495A1 (ja) * | 2015-07-29 | 2017-02-02 | Eaファーマ株式会社 | シクロプロパン誘導体及びそれを含有する医薬 |
TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
CN108602807B (zh) * | 2016-02-05 | 2022-05-13 | Ea制药株式会社 | 杂环磺酰胺衍生物及含有其的药物 |
CN109476640B (zh) * | 2016-07-20 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 双环脯氨酸化合物 |
EP3497093B1 (en) * | 2016-08-12 | 2021-09-15 | F. Hoffmann-La Roche AG | Sulfonyl pyridyl trp inhibitors |
CN110869346B (zh) * | 2017-07-27 | 2024-03-29 | 密歇根大学董事会 | 纤维蛋白溶酶原活化物抑制因子-1(pai-1)抑制剂和使用方法 |
CN109734564B (zh) * | 2019-01-31 | 2022-09-16 | 南京理工大学 | 一种合成三氟乙基芳香族类化合物的方法 |
FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐,制备方法及用途 |
IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
WO2024099403A1 (zh) * | 2022-11-10 | 2024-05-16 | 北京普祺医药科技股份有限公司 | 一种具有软药性质的硫醚类化合物、药物组合物及其用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
US8586748B2 (en) | 2008-04-09 | 2013-11-19 | Boehringer Ingelheim International Gmbh | 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10 |
WO2010141805A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
WO2013108857A1 (ja) * | 2012-01-17 | 2013-07-25 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
JP6152093B2 (ja) * | 2012-04-24 | 2017-06-21 | Eaファーマ株式会社 | スルホンアミド誘導体及びその医薬用途 |
EP2937335A4 (en) * | 2012-12-18 | 2016-09-14 | Ea Pharma Co Ltd | HETEROCYCLIC AMID DERIVATIVE AND MEDICAMENT THEREWITH |
US10194595B2 (en) * | 2013-05-30 | 2019-02-05 | Cnh Industrial America Llc | Bale effect linkage and methods of use |
US20160128529A1 (en) * | 2014-11-07 | 2016-05-12 | Biran Ndiaye | Surface Cleaning Appliance with Motorized Wand |
-
2015
- 2015-01-28 EP EP15742861.6A patent/EP3101015B1/en active Active
- 2015-01-28 JP JP2015559992A patent/JP6473420B2/ja active Active
- 2015-01-28 WO PCT/JP2015/052415 patent/WO2015115507A1/ja active Application Filing
- 2015-01-28 CN CN201580006396.3A patent/CN106458952B/zh active Active
- 2015-01-28 CA CA2938198A patent/CA2938198A1/en not_active Abandoned
- 2015-01-28 RU RU2016134749A patent/RU2016134749A/ru unknown
- 2015-01-28 ES ES15742861T patent/ES2759310T3/es active Active
- 2015-01-28 KR KR1020167023562A patent/KR20160135183A/ko not_active Application Discontinuation
- 2015-01-28 BR BR112016017317-1A patent/BR112016017317B1/pt active IP Right Grant
- 2015-01-28 MX MX2016009794A patent/MX2016009794A/es unknown
- 2015-01-28 AU AU2015211852A patent/AU2015211852A1/en not_active Abandoned
-
2016
- 2016-07-28 US US15/222,178 patent/US10626112B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112016017317B1 (pt) | 2023-04-11 |
JP6473420B2 (ja) | 2019-02-20 |
EP3101015B1 (en) | 2019-09-18 |
BR112016017317A2 (pt) | 2017-10-17 |
JPWO2015115507A1 (ja) | 2017-03-23 |
WO2015115507A1 (ja) | 2015-08-06 |
AU2015211852A1 (en) | 2016-09-15 |
KR20160135183A (ko) | 2016-11-25 |
US20160332999A1 (en) | 2016-11-17 |
CN106458952A (zh) | 2017-02-22 |
CA2938198A1 (en) | 2015-08-06 |
US10626112B2 (en) | 2020-04-21 |
RU2016134749A (ru) | 2018-03-02 |
CN106458952B (zh) | 2019-09-27 |
MX2016009794A (es) | 2017-01-13 |
ES2759310T3 (es) | 2020-05-08 |
EP3101015A1 (en) | 2016-12-07 |
EP3101015A4 (en) | 2017-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
BR112017027951A2 (pt) | composto inibitório de brk | |
BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
BR112017023233A2 (pt) | métodos para tratamento de câncer | |
BR112019002576A2 (pt) | composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo | |
BR112016018548A2 (pt) | composto, ácido, medicamento, e, uso de um composto. | |
NZ735000A (en) | Methods for the treatment of abnormal involuntary movement disorders | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
BR112014025711A2 (pt) | composto, medicamento, e, uso de um composto | |
NZ732511A (en) | Small molecule inhibitors of egfr and pi3k | |
MY197698A (en) | Oxysterols and methods of use thereof | |
BR112015022041A2 (pt) | derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas | |
PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
BR112017010440A2 (pt) | administração sublingual de riluzol | |
BR112017010423A2 (pt) | formulação sublingual de riluzol | |
BR112016020260A8 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
BR112017008178A2 (pt) | ativador do canal de kcnq2-5 | |
PH12017500747B1 (en) | Heterocyclic compound | |
BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
BR112016007620A2 (pt) | composto, medicamento, e, uso de um composto | |
BR112017010471A2 (pt) | compostos de di-hidropirimidin-2-ona e usos médicos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2015, OBSERVADAS AS CONDICOES LEGAIS |